Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis

Determining the impact of ex-vivo lung perfusion on hospital costs for lung transplantation: A retrospective cohort study

(2022) John Kenneth Peel et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis

(2020) Sanja Stanojevic et al.   Journal of Cystic Fibrosis

Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines

(2019) Kathleen J. Ramos et al.   Journal of Cystic Fibrosis

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis

(2018) Hong-xia Wu et al.   ADVANCES IN THERAPY

The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF

(2018) Paul D.W. Eckford et al.   Journal of Cystic Fibrosis

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

(2017) Michael W Konstan et al.   Lancet Respiratory Medicine

Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation

(2016) Piyameth Dilokthornsakul et al.   EUROPEAN RESPIRATORY JOURNAL

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

(2015) Claire E. Wainwright et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis

(2014) Penny Whiting et al.   HEALTH TECHNOLOGY ASSESSMENT

Cost effectiveness of newborn screening for cystic fibrosis: A simulation study

(2013) L. Nshimyumukiza et al.   Journal of Cystic Fibrosis

The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis

(2013) Paul Tappenden et al.   PHARMACOECONOMICS

A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation

(2011) Bonnie W. Ramsey et al.   NEW ENGLAND JOURNAL OF MEDICINE